Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

Wright, George L.; Grob, B. Mayer; Haley, Cara; Grossman, Katie; Newhall, Kathy; Petrylak, Daniel P.; Troyer, John K.; Konchuba, Alice M.; Schellhammer, Paul F.; Moriarty, Richard P.

doi:10.1016/s0090-4295(96)00184-7

Cited by 568 publications

(367 citation statements)

References 23 publications

Supporting

Mentioning

347

Contrasting

Unclassified

Order By: Relevance

“…PSMA is highly expressed by virtually all prostate cancers (17)(18)(19)(20) and the neovasculature of most nonprostate solid tumors including breast and lung cancers (21,22). PSMA is currently the focus of several diagnostic and therapeutic clinical trials for prostate and nonprostate cancers (17)(18)(19)(20)23). Although PLGA-PEG NPs are effective at noncovalent encapsulation and subsequent release of hydrophobic drugs like docetaxel (Dtxl), the encapsulation of hydrophilic drugs may result in poor loading and drug encapsulation efficiency.…”

mentioning

confidence: 99%

Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

Kolishetti

Dhar

Valencia

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

543

429

View full text Add to dashboard Cite

The genomic revolution has identified therapeutic targets for a plethora of diseases, creating a need to develop robust technologies for combination drug therapy. In the present work, we describe a self-assembled polymeric nanoparticle (NP) platform to target and control precisely the codelivery of drugs with varying physicochemical properties to cancer cells. As proof of concept, we codelivered cisplatin and docetaxel (Dtxl) to prostate cancer cells with synergistic cytotoxicity. A polylactide (PLA) derivative with pendant hydroxyl groups was prepared and conjugated to a platinum(IV) [Pt(IV)] prodrug, c,t,c-½PtðNH 3 Þ 2 ðO 2 CCH 2 CH 2 COOHÞðOHÞCl 2 [PLAPt(IV)]. A blend of PLA-Pt(IV) functionalized polymer and carboxylterminated poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) copolymer in the presence or absence of Dtxl, was converted, in microfluidic channels, to NPs with a diameter of ∼100 nm. This process resulted in excellent encapsulation efficiency (EE) and high loading of both hydrophilic platinum prodrug and hydrophobic Dtxl with reproducible EEs and loadings. The surface of the NPs was derivatized with the A10 aptamer, which binds to the prostatespecific membrane antigen (PSMA) on prostate cancer cells. These NPs undergo controlled release of both drugs over a period of 48-72 h. Targeted NPs were internalized by the PSMA-expressing LNCaP cells via endocytosis, and formation of cisplatin 1,2-d(GpG) intrastrand cross-links on nuclear DNA was verified. In vitro toxicities demonstrated superiority of the targeted dual-drug combination NPs over NPs with single drug or nontargeted NPs. This work reveals the potential of a single, programmable nanoparticle to blend and deliver a combination of drugs for cancer treatment.chemotherapy | drug delivery | polymer-drug conjugate | targeting | temporal release

show abstract

mentioning

confidence: 99%

Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

Kolishetti

Dhar

Valencia

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

543

429

View full text Add to dashboard Cite

show abstract

“…1,2 PSMA is an attractive target for immunotherapy because it is highly expressed in normal and neoplastic prostatic tissue and the neovasculature of solid tumors, with limited expression in normal tissue. [3][4][5][6][7] PSMA-specific monoclonal antibodies (MAb) have been used for in vivo diagnostic and therapeutic applications without adverse events. [8][9][10][11] Biochemical and objective measurable disease responses were reported in some patients treated with radionuclide conjugates of a humanized MAb, J591, that binds to the extracellular domain of PSMA.…”

mentioning

confidence: 99%

Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination

Gregor

Wolchok

Turaga

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is a prototypical differentiation antigen expressed on normal and neoplastic prostate epithelial cells, and on the neovasculature of many solid tumors. Monoclonal antibodies specific for PSMA are in development as therapeutic agents. Methodologies to actively immunize against PSMA may be limited by immunologic ignorance and/or tolerance that restrict the response to self-antigens. Our studies have previously shown that xenogeneic immunization with DNA vaccines encoding melanosomal differentiation antigens induces immunity in a mouse melanoma model. Here we apply this approach to PSMA to establish proof of principle in a mouse model. Immunization with xenogeneic human PSMA protein or DNA induced antibodies to both human and mouse PSMA in mice. Monoclonal antibodies specific for mouse PSMA were generated to analyze antibody isotypes and specificity for native and denatured PSMA at the clonal level. Most antibodies recognized denatured PSMA, but C57BL/6 mice immunized with xenogeneic PSMA DNA followed by a final boost with xenogeneic PSMA protein yielded autoantibodies that reacted with native folded mouse PSMA. Monoclonal antibodies were used to confirm the expression of PSMA protein in normal mouse kidney. These results establish the basis for clinical trials to test PSMA DNA vaccines in patients with solid tumors that either express PSMA directly or that depend on normal endothelial cells expressing PSMA for their continued growth. ' 2005 Wiley-Liss, Inc.

show abstract

“…We chose PSMA as the target antigen since it is largely prostatespecific, it remains attached to the outer cell surface (making it accessible on live cells), its steady-state levels increase approximately 10-fold in prostate tumors and it is expressed by most prostate cancer cells (particularly in advanced disseminated disease). [22][23][24] There are also interesting reports that PSMA is selectively expressed at significant levels by the neovasculature of many tumor types. 4,5 There is a concern that low levels of PSMA expressed by several normal nonprostatic tissues might lead to deleterious systemic side effects from treatment with PSMA antibodies or immunization with PSMA, but clinical trials and model studies to date have not supported this.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of prostate‐specific membrane antigen (PSMA)‐positive tumor growth by vaccination with either full‐length or the C‐terminal end of PSMA

Kuratsukuri

Sone

Wang

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

Cited by 568 publications

References 23 publications

Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination

Inhibition of prostate‐specific membrane antigen (PSMA)‐positive tumor growth by vaccination with either full‐length or the C‐terminal end of PSMA

Contact Info

Product

Resources

About